NasdaqGM - Delayed Quote • USD
TScan Therapeutics, Inc. (TCRX)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:05 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 4 |
| Avg. Estimate | -0.26 | -0.25 | -1.04 | -1.14 |
| Low Estimate | -0.27 | -0.27 | -1.11 | -1.18 |
| High Estimate | -0.24 | -0.23 | -0.98 | -1.08 |
| Year Ago EPS | -0.93 | -0.51 | -1.36 | -1.04 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 3.97M | 4.07M | 16.51M | 11.37M |
| Low Estimate | 2.5M | 2.5M | 10M | -- |
| High Estimate | 5.4M | 5.51M | 22.5M | 21.98M |
| Year Ago Sales | 6.8M | 3.15M | 21.05M | 16.51M |
| Sales Growth (year/est) | -41.60% | 29.30% | -21.60% | -31.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.74 | -0.78 | -0.45 | -0.29 |
| EPS Actual | -0.93 | -0.51 | -0.24 | -0.21 |
| Difference | -0.19 | 0.27 | 0.21 | 0.08 |
| Surprise % | -25.70% | 34.60% | 46.70% | 27.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.26 | -0.25 | -1.04 | -1.14 |
| 7 Days Ago | -0.25 | -0.26 | -1.05 | -1.11 |
| 30 Days Ago | -0.25 | -0.26 | -1.05 | -1.11 |
| 60 Days Ago | -0.26 | -0.27 | -1.2 | -1.15 |
| 90 Days Ago | -0.26 | -0.27 | -1.2 | -1.15 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | -- |
| Up Last 30 Days | -- | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | TCRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 72.00% | -- | -- | 1.50% |
| Next Qtr. | 51.00% | -- | -- | 11.40% |
| Current Year | 23.50% | -- | -- | 5.20% |
| Next Year | -9.60% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 4/23/2024 |
| Maintains | Barclays: Overweight to Overweight | 3/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/7/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
| Initiated | Wedbush: Outperform | 6/22/2023 |
Related Tickers
CGEM Cullinan Therapeutics, Inc.
18.89
+13.32%
SYRE Spyre Therapeutics, Inc.
32.99
-3.68%
IGMS IGM Biosciences, Inc.
7.96
+3.38%
BCYC Bicycle Therapeutics plc
22.67
-0.04%
EWTX Edgewise Therapeutics, Inc.
16.11
+2.94%
IMCR Immunocore Holdings plc
58.47
+2.02%
CNTA Centessa Pharmaceuticals plc
9.46
+0.64%
HOWL Werewolf Therapeutics, Inc.
6.39
-0.78%
VIGL Vigil Neuroscience, Inc.
2.7700
+4.53%
FULC Fulcrum Therapeutics, Inc.
7.28
-2.15%